Gene: MYOCD

93649
MYCD
myocardin
protein-coding
17p12
Ensembl:ENSG00000141052 MIM:606127 Vega:OTTHUMG00000058767 UniprotKB:Q8IZQ8
NG_012972.1
PubMed
0   ANCO-SNPs
OD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.396e-1 (AD)  3.561e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
BMX0.903
TRABD2B0.898
ALX40.884
TBX180.882
SLC22A80.87
CDC20B0.869
PLN0.865
SLC13A40.862
OGN0.861
OR51E10.858

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASPDH-0.345
CCDC24-0.328
SLC25A10-0.324
SORCS2-0.323
HAGHL-0.32
C9orf24-0.307
BDH1-0.303
HHATL-0.302
FGF22-0.301
DBP-0.301

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of MYOCD mRNA"19114083
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of MYOCD gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of MYOCD mRNA16483693
D001151ArsenicArsenic affects the methylation of MYOCD gene25304211
C006632arsenic trioxidearsenic trioxide results in increased expression of MYOCD mRNA26705709
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in decreased expression of MYOCD mRNA"18687144
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYOCD mRNA22178795
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MYOCD mRNA22316170
D001564Benzo(a)pyreneAHR protein affects the reaction [Benzo(a)pyrene affects the expression of MYOCD mRNA]22228805
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to MYOCD promoter]19654925
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MYOCD mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of MYOCD mRNA"20382639
C006780bisphenol Abisphenol A results in decreased expression of MYOCD mRNA27685785
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in decreased expression of MYOCD mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of MYOCD mRNA25181051
C027561butylbenzyl phthalatebutylbenzyl phthalate results in decreased expression of MYOCD mRNA26472102
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of MYOCD mRNA26472102
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of MYOCD mRNA27392435
D002945CisplatinCisplatin results in decreased expression of MYOCD mRNA27392435
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in decreased expression of MYOCD mRNA26472102
C007379diethyl phthalatediethyl phthalate results in decreased expression of MYOCD mRNA26472102
C024629dimethyl phthalatedimethyl phthalate results in decreased expression of MYOCD mRNA26472102
C034171di-n-pentyl phthalatedi-n-pentyl phthalate results in decreased expression of MYOCD mRNA26472102
C118739entinostatentinostat results in decreased expression of MYOCD mRNA27188386
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MYOCD mRNA17942748
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of MYOCD mRNA23300682
D004397FonofosFonofos results in increased methylation of MYOCD promoter22847954
D005557FormaldehydeFormaldehyde results in increased expression of MYOCD mRNA28937961
C039281furanfuran results in increased methylation of MYOCD gene22079235
C001277geldanamycingeldanamycin results in increased expression of MYOCD mRNA26705709
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of MYOCD mRNA27392435
C544151jinfukangjinfukang results in decreased expression of MYOCD mRNA27392435
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of MYOCD mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of MYOCD mRNA"25554681
D009532NickelNickel results in decreased expression of MYOCD mRNA24768652|2558310
C028007nickel monoxidenickel monoxide results in decreased expression of MYOCD mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of MYOCD mRNA22714537
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of MYOCD mRNA27935865
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of MYOCD mRNA26272509
D010278ParathionParathion results in increased methylation of MYOCD promoter22847954
D010656PhenylephrineMYOCD protein affects the reaction [Phenylephrine results in increased expression of ACTA2 mRNA]16556869
D010656PhenylephrineMYOCD protein affects the reaction [Phenylephrine results in increased expression of NPPB mRNA]16556869
D010656PhenylephrineMYOCD protein promotes the reaction [Phenylephrine results in increased expression of MYL2 protein]14676212
D010656PhenylephrineMYOCD protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]14676212
D010656PhenylephrinePhenylephrine promotes the reaction [MYOCD protein binds to NPPA promoter]16556869
D010656PhenylephrinePhenylephrine results in increased expression of MYOCD mRNA16556869
D010656PhenylephrinePhenylephrine results in increased expression of MYOCD protein16556869
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of MYOCD mRNA26272509
C006253pirinixic acidpirinixic acid results in increased expression of MYOCD mRNA16985257
D011374ProgesteroneProgesterone results in increased expression of MYOCD mRNA20864642
C059514resveratrolresveratrol results in decreased expression of MYOCD mRNA20797428
C093642SB 203580SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MYOCD mRNA]21712382
C009277sodium arsenatesodium arsenate results in increased expression of MYOCD mRNA21795629
C012568terbufosterbufos results in increased methylation of MYOCD promoter22847954
D013739Testosterone[bisphenol A co-treated with Testosterone] results in decreased expression of MYOCD mRNA26496021
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MYOCD mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to MYOCD promoter]19654925
C009495titanium dioxidetitanium dioxide results in decreased expression of MYOCD mRNA23557971
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of MYOCD mRNA20133372
D014028Tobacco Smoke PollutionTobacco Smoke Pollution promotes the reaction [KLF4 protein binds to MYOCD promoter]23967268
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of MYOCD mRNA23967268
D014241TrichloroethyleneTrichloroethylene results in increased methylation of MYOCD gene27618143
C012589trichostatin Atrichostatin A results in increased expression of MYOCD mRNA24935251|2670570
D014544Uridine TriphosphateUridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein]14676212
D014544Uridine TriphosphateUridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein]14676212
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MYOCD mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of MYOCD mRNA23179753|2438349
D014638VanadatesVanadates results in increased expression of MYOCD mRNA22714537
C581157XL147[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of MYOCD mRNA27935865

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IDA19797053  
GO:0001076transcription factor activity, RNA polymerase II transcription factor binding-IEA-  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IDA22157009  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IDA19578358  
GO:0003713transcription coactivator activity-IEA-  
GO:0005515protein binding-IPI12397177  14970199  19797053  25416956  
GO:0008134transcription factor binding-IPI16054032  
GO:0035035histone acetyltransferase binding-IEA-  
GO:0042826histone deacetylase binding-IEA-  
GO:0061629RNA polymerase II sequence-specific DNA-binding transcription factor binding-ISS-  
GO:0070412R-SMAD binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0001560regulation of cell growth by extracellular stimulus-IEA-  
GO:0001570vasculogenesis-IEA-  
GO:0001666response to hypoxia-IEP19098903  
GO:0003231cardiac ventricle development-IEA-  
GO:0003257positive regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation-IDA15907818  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0008284positive regulation of cell proliferation-IEA-  
GO:0008285negative regulation of cell proliferation-IDA18451334  
GO:0010667negative regulation of cardiac muscle cell apoptotic process-IEA-  
GO:0010832negative regulation of myotube differentiation-IEA-  
GO:0030511positive regulation of transforming growth factor beta receptor signaling pathway-IEA-  
GO:0035051cardiocyte differentiation-NAS12640126  
GO:0035065regulation of histone acetylation-ISS-  
GO:0035886vascular smooth muscle cell differentiation-IEA-  
GO:0043388positive regulation of DNA binding-IEA-  
GO:0043954cellular component maintenance-IEA-  
GO:0045661regulation of myoblast differentiation-IEA-  
GO:0045736negative regulation of cyclin-dependent protein serine/threonine kinase activity-IDA18451334  
GO:0045893positive regulation of transcription, DNA-templated-IDA19797053  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA14970199  17215356  19578358  
GO:0045987positive regulation of smooth muscle contraction-IDA17215356  
GO:0048286lung alveolus development-IEA-  
GO:0048565digestive tract development-IEA-  
GO:0051091positive regulation of DNA-binding transcription factor activity-IDA19098903  
GO:0051145smooth muscle cell differentiation-IBA21873635  
GO:0051145smooth muscle cell differentiation-IMP14970199  
GO:0051150regulation of smooth muscle cell differentiation-TAS17215356  
GO:0051152positive regulation of smooth muscle cell differentiation-IDA18451334  
GO:0055007cardiac muscle cell differentiation-IBA21873635  
GO:0055007cardiac muscle cell differentiation-ISS-  
GO:0055012ventricular cardiac muscle cell differentiation-IEA-  
GO:0060065uterus development-IEA-  
GO:0060157urinary bladder development-IEA-  
GO:0097070ductus arteriosus closure-IEA-  
GO:1900222negative regulation of amyloid-beta clearance-IMP19098903  
GO:1900239regulation of phenotypic switching-IEA-  
GO:1904706negative regulation of vascular smooth muscle cell proliferation-IEA-  
GO:1904753negative regulation of vascular associated smooth muscle cell migration-IEA-  
GO:2000587negative regulation of platelet-derived growth factor receptor-beta signaling pathway-IEA-  
GO:2000721positive regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation-IDA15907818  
GO:2000724positive regulation of cardiac vascular smooth muscle cell differentiation-ISS-  
GO:2000727positive regulation of cardiac muscle cell differentiation-IDA18451334  
GO:2001015negative regulation of skeletal muscle cell differentiation-IDA18451334  
GO ID GO Term Qualifier Evidence PubMed
GO:0000790nuclear chromatin-IEA-  
GO:0005634nucleus-IDA14970199  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
20560679Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. (2010 Jun 1)Fonseca FMol Diagn Ther